Inmed Pharmaceuticals Inc (INM)

$1.10 +0.03 (2.80%)
Market Cap 3.17M
Revenue (ttm) 4.94M
Net Income (ttm) -8.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -165.18%
Debt to Equity Ratio 0.00
Volume 77,100
Avg Vol 424,224
Day's Range N/A - N/A
Shares Out 2.80M
Stochastic %K 3%
Beta 0.33
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
Space0
Space0 Jan. 15 at 5:32 PM
$INM previously stated it was preparing for an IND submission and a pre-IND meeting with the FDA. It has now been over two months with no update or timeline provided. Shareholders would appreciate clarification.
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Jan. 9 at 8:21 PM
$INM RELEASE THE GODKIN PARTICULATE
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Jan. 9 at 8:20 PM
$INM $LABU $TLRY The black swan flappeth her holy wing, the biotech world as you know it will cease to exist come Monday. God bless
2 · Reply
Silver_Bullet26
Silver_Bullet26 Jan. 8 at 10:15 PM
$TLRY $INM Both looking to run
1 · Reply
Space0
Space0 Jan. 8 at 8:00 PM
$INM any news?
0 · Reply
Suh420
Suh420 Jan. 7 at 2:27 PM
$INM better balance sheet and spikeability than ASBP.
0 · Reply
zeph1985
zeph1985 Jan. 5 at 8:45 PM
$INM DCX..
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:45 PM
$INM scam
0 · Reply
alfredaita
alfredaita Dec. 31 at 9:02 PM
$INM straight to zero: The collapse continues. Watch out here comes the reverse split soon. In a theater near you.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 31 at 7:42 PM
$INM RSI: 38.12, MACD: -0.0992 Vol: 0.10, MA20: 1.27, MA50: 1.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on INM
InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

Dec 17, 2025, 8:59 PM EST - 4 weeks ago

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

InMed Announces Results of 2025 Annual General and Special Meeting

Dec 17, 2025, 8:00 PM EST - 4 weeks ago

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Provides Update on BayMedica Commercial Business

Dec 12, 2025, 5:31 PM EST - 5 weeks ago

InMed Provides Update on BayMedica Commercial Business

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 18, 2025, 7:30 AM EST - 2 months ago

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:51 PM EST - 2 months ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 3 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 23, 2025, 8:30 AM EDT - 4 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 16, 2025, 1:39 PM EDT - 4 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 1:33 PM EDT - 4 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jul 28, 2025, 7:00 AM EDT - 6 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 27, 2025, 7:00 AM EDT - 7 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 7 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025, 7:00 AM EDT - 7 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Jun 13, 2025, 4:30 PM EDT - 7 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025, 6:00 PM EDT - 8 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 1 year ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025, 7:30 AM EST - 1 year ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 22, 2025, 7:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025, 7:30 AM EST - 1 year ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 1 year ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 1 year ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 1 year ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 2 years ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 2 years ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 2 years ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 2 years ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 7:15 PM EDT - 2 years ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 2 years ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Space0
Space0 Jan. 15 at 5:32 PM
$INM previously stated it was preparing for an IND submission and a pre-IND meeting with the FDA. It has now been over two months with no update or timeline provided. Shareholders would appreciate clarification.
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Jan. 9 at 8:21 PM
$INM RELEASE THE GODKIN PARTICULATE
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Jan. 9 at 8:20 PM
$INM $LABU $TLRY The black swan flappeth her holy wing, the biotech world as you know it will cease to exist come Monday. God bless
2 · Reply
Silver_Bullet26
Silver_Bullet26 Jan. 8 at 10:15 PM
$TLRY $INM Both looking to run
1 · Reply
Space0
Space0 Jan. 8 at 8:00 PM
$INM any news?
0 · Reply
Suh420
Suh420 Jan. 7 at 2:27 PM
$INM better balance sheet and spikeability than ASBP.
0 · Reply
zeph1985
zeph1985 Jan. 5 at 8:45 PM
$INM DCX..
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:45 PM
$INM scam
0 · Reply
alfredaita
alfredaita Dec. 31 at 9:02 PM
$INM straight to zero: The collapse continues. Watch out here comes the reverse split soon. In a theater near you.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 31 at 7:42 PM
$INM RSI: 38.12, MACD: -0.0992 Vol: 0.10, MA20: 1.27, MA50: 1.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 24 at 3:20 PM
$TLRY The writing is on the wall, heed this warning or perish like all those who invested many moon ago. Every nig with a nog grows dope thanks to Trudeau science fair, the only companies who survive this shitshow will be high margin synthetic producers like $INM
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 22 at 8:04 PM
$TLRY $ACB We the people demand kosher cannabinoids, with current DEI policy no devote servant of Jehovah could dare partake of the sacred plant $INM
1 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 22 at 5:19 PM
$TLRY $ACB Synthesized cannabinoids are the future, Resistance is Futile $INM
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 22 at 5:17 PM
$INM Release the Godkin Particulate to the masses humanity has suffered long enough $MBOT
0 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 19 at 12:06 AM
$TLRY Do not resist destiny, when the black swan flaps her mighty wing the entire biotech world will crumble. Release the God Cannabinoids $INM
0 · Reply
RageBaitSupremacist
RageBaitSupremacist Dec. 18 at 11:46 PM
$TLRY Dr Oz confirms as early as this April people on Medicare and Medicaid can receive CBD products from doctors.... VA will obviously follow.. Yuge..$INM CBD Alzheimer's drug coming soon https://www.youtube.com/live/WrRhi9LZS3k?si=WIVGfZmQ16C5IQrI
0 · Reply
EDSTER1963
EDSTER1963 Dec. 18 at 10:53 PM
$INM so had a conversation earlier with a couple of people who thought they were smarter than everyone else in the room. They're stated position was that with Trump making the move that he was making it was going to just open up the floodgates for the federal government to pay for everybody's weed. All I said to them was it was an executive order and help somebody refine their point of view when they said that it was allowing Medicaid and the VA to pay for prescription marijuana which was absolutely untrue. My point then was that there is no guarantees. And here's an article that just puts a fine point on it https://www.msn.com/en-us/news/politics/house-republicans-demand-trump-reverse-course-after-strongly-considering-marijuana-executive-order/ar-AA1SBO0C
1 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 18 at 10:29 PM
$INM To quench the AI thirst for water humans must make sacrifice. Not one drop of precious liquid will be wasted growing your abominate drugs. $TLRY
1 · Reply
LatteLove
LatteLove Dec. 18 at 7:45 PM
$INM seems scamy.
0 · Reply
RageBaitSupremacist
RageBaitSupremacist Dec. 18 at 7:37 PM
$INM Trump just rescheduled marijuana from schedule 1 to schedule 3 drug. That means VA and Medicaid will be paying for marijuana prescriptions for the millions of people on disability with a prescription for it.. it's huge.. and INM is about to get an FDA approved Alzheimer's CBD drug.. $TLRY $ACB
1 · Reply
SNUNEYMUXWSTOCKS
SNUNEYMUXWSTOCKS Dec. 18 at 6:20 PM
$INM AI demands water or blood, humanity cannot waste such precious resource on Marijuana. The age of water rationing is upon us. $TLRY
0 · Reply
RageBaitSupremacist
RageBaitSupremacist Dec. 18 at 5:39 PM
My marijuana cannabis watch list is looking good starting to heat up$UGRO looking really good... $INM still looking good hasn't been found yet it's gonna fucking send hard when more people start to see it... 👀👀
0 · Reply